Takuya Egami
Impact in
- Oncology top 10%
- Pancreatic and Hepatic Oncology Research
- Cancer Cells and Metastasis
-
- Cancer Genomics and Diagnostics
Papers in
- Co-authors
- Masao Tanaka (15 shared papers)Kenoki Ohuchida (14 shared papers)Kazuhiro Mizumoto (14 shared papers)Eishi Nagai (5 shared papers)Hayato Fujita (7 shared papers)Jun Yu (5 shared papers)Hiroki Toma (6 shared papers)Lin Cui (7 shared papers)
In The Last Decade
Takuya Egami
17 papers receiving 387 citations
Peers
Comparison fields: 5 of 56
- Oncology 247
- Cancer Research 82
- Biotechnology 40
- Molecular Biology 192
- Immunology and Allergy 15
Countries citing papers authored by Takuya Egami
This map shows the geographic impact of Takuya Egami's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Takuya Egami with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Takuya Egami more than expected).
Fields of papers citing papers by Takuya Egami
This network shows the impact of papers produced by Takuya Egami. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Takuya Egami. The network helps show where Takuya Egami may publish in the future.
Co-authors
The 25 scholars most cited alongside Takuya Egami, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 26 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer. | 2008 | 93 |
| 2 | 2006 | 76 | |
| 3 | 2009 | 62 | |
| 4 | Increased expression of ADAM 9 and ADAM 15 mRNA in pancreatic cancer. | 2007 | 32 |
| 5 | 2008 | 22 | |
| 6 | 2010 | 21 | |
| 7 | 2008 | 20 | |
| 8 | 2008 | 14 | |
| 9 | 2009 | 13 | |
| 10 | A Feasibility Study of Neoadjuvant XELOX Without Radiotherapy for Locally Advanced Lower Rectal Cancer. | 2016 | 12 |
| 11 | 2010 | 9 | |
| 12 | 2008 | 8 | |
| 13 | 2010 | 6 | |
| 14 | Adenoviral therapy is more effective in gemcitabine-resistant pancreatic cancer than in gemcitabine-sensitive cells. | 2011 | 5 |
| 15 | 2003 | 4 | |
| 16 | 2009 | 3 | |
| 17 | 2016 | 1 | |
| 18 | 2005 | 1 | |
| 19 | 2015 | 1 | |
| 20 | 2017 | 0 |
About Takuya Egami
Takuya Egami is a scholar working on Oncology, Surgery, Genetics, Biotechnology and Molecular Biology, having authored 26 papers that have together received 403 indexed citations. Recurring topics across this work include Cancer Research and Treatments (7 papers), Virus-based gene therapy research (7 papers), CAR-T cell therapy research (5 papers), Pancreatic and Hepatic Oncology Research (5 papers), Intraperitoneal and Appendiceal Malignancies (3 papers), Cell Adhesion Molecules Research (2 papers), Liver physiology and pathology (2 papers) and Glycosylation and Glycoproteins Research (2 papers). The work is most often cited by research in Oncology (247 citations), Cancer Research (82 citations), Biotechnology (40 citations), Molecular Biology (192 citations) and Immunology and Allergy (15 citations). Takuya Egami has collaborated with scholars based in Japan and Canada. Frequent co-authors include Masao Tanaka, Kenoki Ohuchida, Kazuhiro Mizumoto, Eishi Nagai, Hayato Fujita, Jun Yu, Hiroki Toma, Lin Cui, Hiroyuki Konomi and Hiroshi Yamaguchi. Their work appears in journals such as Cancer Science, Clinical Cancer Research, Digestive Diseases and Sciences, Cancer Letters and Cancer Gene Therapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.